Belite Bio, Inc (BLTE)
$28.02
Rating:
Recommendation:
-
| Symbol | BLTE |
|---|---|
| Price | $28.02 |
| Beta | 0.000 |
| Volume Avg. | 0.01M |
| Market Cap | 696.785M |
| Shares () | - |
| 52 Week Range | 8.8-44.7 |
| 1y Target Est | - |
| DCF Unlevered | BLTE DCF -> | |
|---|---|---|
| DCF Levered | BLTE LDCF -> | |
| ROE | -143.25% | Strong Sell |
| ROA | -18.93% | Sell |
| Operating Margin | - | |
| Debt / Equity | 2.87% | Neutral |
| P/E | -90.39 | Strong Sell |
| P/B | 13.60 | Strong Buy |
Latest BLTE news
About
Download (Excel)Belite Bio, Inc, a clinical-stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting atrophic age-related macular degeneration and autosomal recessive stargardt diseases. Its lead product candidate is LBS-008, an oral once-a-day treatment that can reduce and maintain the delivery of vitamin A to the eye to reduce the accumulation of toxic vitamin A by-products in ocular tissue that is in phase 3 clinical trial. The company is also developing LBS-009, an anti-retinol binding protein 4 oral therapy targeting liver disease, including non-alcoholic fatty liver disease, nonalcoholic steatohepatitis, and type 2 diabetes, which is in the preclinical development phase. Belite Bio, Inc was founded in 2016 and is based in San Diego, California. Belite Bio, Inc operates as a subsidiary of Lin Bioscience International Ltd.